5.18
+0.04(+0.78%)
Currency In USD
| Previous Close | 5.14 |
| Open | 5.15 |
| Day High | 5.35 |
| Day Low | 5.12 |
| 52-Week High | 7.29 |
| 52-Week Low | 1.67 |
| Volume | 1.98M |
| Average Volume | 4.35M |
| Market Cap | 507.57M |
| PE | -6.56 |
| EPS | -0.79 |
| Moving Average 50 Days | 5.3 |
| Moving Average 200 Days | 4 |
| Change | 0.04 |
aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
GlobeNewswire Inc.
Jul 22, 2025 12:00 PM GMT
Topline results expected in the third quarter of 2025.SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-
aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes
GlobeNewswire Inc.
Jun 26, 2025 12:00 PM GMT
SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetas
aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)
GlobeNewswire Inc.
Jun 04, 2025 12:00 PM GMT
Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. Efzofitimod was generally safe and well tolerated at all doses. SAN DIEGO, J